NCT00441337View on ClinicalTrials.gov

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Carcinoma, Non-Small-Cell LungColorectal CancerMalignant MelanomaRenal CancerProstate Cancer
Interventions
BIOLOGICAL

MDX-1106

patients will receive a single dose of MDX-1106 as a 60 minute infusion.

Trial Locations (4)

21231

Johns Hopkins Unv., School of Medicine, Baltimore

28078

Carolina BioOncology Institute, PLLC, Huntersville

48202

Henry Ford Health System, Detroit

63110

Washington University School of Medicine - Barnes Jewish Hospital, St Louis

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY